



# Small Business and Industry Assistance Knowledge Management and Modernization of Regulatory Quality Assessment and Submissions at FDA



January 29, 2025

Version 6 – Updated December 23, 2024

For files and resources, please visit  
[The Event Page on SBIAevents.com](#)

[Add Event to Your Calendar](#)

## AGENDA

All times are Eastern (EST UTC-4)

[View Start Time on World Clock](#)

### Wednesday, January 29, 2025

9:00 – 9:15

#### Administrative Overview

**Brenda Stodart, PharmD, MS, BCGP, RAC**

*Captain, United States Public Health Service (USPHS)  
Director, Small Business, and Industry Assistance (SBIA)  
Division of Drug Information (DDI) | Office of Communications (OCOMM)  
Center for Drug Evaluation and Research (CDER)*

9:15 – 9:20

#### Welcome

**Lawrence Yu**

*Director  
Office of Product Quality Assessment II (OPQA II)  
Office of Pharmaceutical Quality (OPQ) | CDER*

9:20 – 9:45

#### Overview of KASA Program

This presentation will give an overview of the KASA program, including current status and future directions.

**Andre Raw**

*Associate Director for Science and Communication  
Office of Product Quality Assessment I (OPQA I)  
OPQ | CDER*

9:45 – 10:30

#### ICH M4A(R2): Advancing Common Technical Document for the Registration of Pharmaceuticals

M4Q(R2) aims to enhance registration efficiency, harness digital technologies, and expedite patient access to pharmaceuticals. It establishes Module 2 as the basis for regulatory assessment, with Module 3 providing support. This presentation will introduce the structure of Modules 2 and 3, highlighting their roles in the registration of pharmaceuticals for human use.

**Lawrence Yu**

*Director  
OPQA II | OPQ | CDER*

**10:30 – 10:45: BREAK**

**Wednesday, January 29, 2025**

10:45 – 11:30

**M4Q(R2) Lifecycle Management Considerations, New Concepts and Next Steps**

This presentation will introduce product lifecycle management considerations from the perspective of M4Q(R2), as well as new concepts such as Overall Product Development Strategy, Overall Control Strategy, and Integrated development. The M4Q(R2) business plan will also be presented.

**Larisa Wu**  
*Associate Director for Science and Communication*  
 OPQA II | OPQ | CDER

11:30 – 12:00

**Q&A Panel**

**Andre Raw, Lawrence Yu, Larisa Wu and Elvira Argus**  
*Biological Reviewer | Office of Gene Therapy (OGT)*  
*Office of Therapeutic Products (OTP)*  
*Center for Biologics Evaluation and Research (CBER)*

**Rakhi Shah**  
*Associate Director for Science and Communication*  
*Office of Pharmaceutical Manufacturing Assessment (OPMA)*  
 OPQ | CDER

**12:00 – 1:00: LUNCH BREAK**

1:00 – 1:45

**ICH M4Q(R2) Revisions: Drug Substance, Materials, and Analytical Procedures**

This presentation will describe the revisions to the Drug Substance, Materials, and Analytical Procedures sections of the ICH M4Q(R2) guideline.

**Elvira Argus**  
*Biological Reviewer*  
 OGT | OTP | CBER

1:45 – 2:30

**ICH M4Q(R2) Revisions: Drug Product, Manufacturing, Facilities and Packaging**

This presentation will cover the M4Q(R2) revisions with respect to product, manufacturing process including packaging of single and multiconstituent products, and facilities.

**Rakhi Shah**  
*Associate Director for Science and Communication*  
 OPMA | OPQ | CDER

2:30 – 2:50

**Q&A Panel**

**Elvira Argus, Rakhi Shah, Larisa Wu, Lawrence Yu**

**2:50 – 3:00: BREAK**

Wednesday, January 29, 2025

3:00 – 3:45

**FDA Pharmaceutical Quality Electronic Data Standards - Objectives**

This presentation will provide an overview of the FDA's pharmaceutical quality chemistry manufacturing and control (PQ/CMC) effort in establishing CMC data standards and data exchange standards to enable structured submissions.

**Geoffrey Wu**  
*Commander | USPHS*  
*Acting Director*  
OPQA 1 | OPQ | CDER

3:45 – 4:05

**Case Study: Data Elements for Solid Oral Dosage Forms**

This presentation will detail data standards and present case studies on data elements of solid oral dosage forms developed in the PQ/CMC project. Such structured data submissions enhance the efficiency of drug product application reviews and support lifecycle knowledge management.

**Zhouxi (Josie) Wang**  
*Senior Biologist*  
OPMA | OPQ | CDER

4:05 – 4:25

**Q&A Panel**

**Geoffrey Wu, Josie Wang**

4:25 – 4:30

**Closing Remarks**

**Geoffrey Wu**  
*Commander | USPHS*  
*Acting Director*  
OPQA 1 | OPQ | CDER

**4:30: ADJOURN WORKSHOP**